CODEN: WJAPAC Impact Factor: 5.48 ISSN: 3049-3013

World Journal of Advance Pharmaceutical Sciences

Volume 3, Issue 5, Page: 12-22 Review Article www.wjaps.com

# IMPACT OF PHARMACOGENOMICS IN PERSONALIZED MEDICINE: CURRENT APPLICATIONS AND FUTURE DIRECTIONS

**Md. Al Amin[1,2]*, Sree Karma Tigga[2], Md. Rezwan Hossain[2], Nusrat Jahan Mim[1], Moazzema Binta Bashar[3]**

[1]Department of Pharmacy, University of Information Technology and Sciences (UITS), Dhaka 1212, Bangladesh.
[2]Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh.
[3]State University of Bangladesh, Dhaka-1461, Bangladesh.

**How to cite this Article:** Md. Al Amin[1,2]*, Sree Karma Tigga[2], Md. Rezwan Hossain[2], Nusrat Jahan Mim[1], Moazzema Binta Bashar[3] (2026). IMPACT OF PHARMACOGENOMICS IN PERSONALIZED MEDICINE: CURRENT APPLICATIONS AND FUTURE DIRECTIONS. World Journal of Advance Pharmaceutical Sciences, 3(5), 12-22.



**Article Info**

**Article Received: 27 February 2026,**

**Article Revised: 17 March 2026,**

**Article Accepted: 07 April 2026.**

**DOI:** https://doi.org/10.5281/zenodo.19925108

***Corresponding author:**

**Md. Al Amin**

Department of Pharmacy, University of Information Technology and Sciences (UITS), Dhaka 1212, Bangladesh.

## ABSTRACT

Pharmacogenomics, the study of how genetic variation affects drug response, is a key component of personalized medicine, offering the potential to optimize therapeutic efficacy while minimizing adverse effects. This review was conducted through a structured literature search of PubMed, Scopus, Web of Science, and Google Scholar, using keywords such as "pharmacogenomics," "personalized medicine," "gene-drug interaction," and "precision therapy," considering articles published in English from 2015 to 2026. Studies reporting mechanistic insights, clinical applications, and computational strategies for pharmacogenomic-guided therapy were included, while non-peer-reviewed or insufficiently detailed studies were excluded. Data were extracted on genetic variants, drug responses, therapeutic areas, and clinical outcomes, and were synthesized to evaluate current trends, challenges, and opportunities. The review identified multiple clinically relevant pharmacogenomic associations, including CYP2C19-guided clopidogrel therapy, TPMT-guided thiopurine dosing, and HER2-targeted therapies in oncology, demonstrating improved drug efficacy, reduced adverse events, and optimized dosing strategies. Emerging tools such as multi-gene panels, next-generation sequencing, and computational predictive models further enhance the ability to translate genetic insights into clinical practice. Despite challenges including limited evidence for certain gene-drug pairs, variability in guidelines, and ethical considerations, pharmacogenomics has shown substantial impact on patient care. In conclusion, pharmacogenomics provides an evidence-driven framework for individualized therapy, enabling safer and more effective treatment decisions, and is poised to play a transformative role in the advancement of personalized medicine.

**KEYWORDS:** Pharmacogenomics, Personalized medicine, Gene-drug interaction, Genetic polymorphism, Clinical pharmacology, Translational medicine.

## INTRODUCTION

Pharmacogenomics, the study of how genetic variation influences drug response, has emerged as a critical pillar of personalized medicine. Unlike traditional pharmacotherapy, which often relies on standardized dosing and a one-size-fits-all approach, pharmacogenomics seeks to tailor treatments to an individual's genetic makeup, optimizing efficacy while

minimizing adverse drug reactions (ADRs).[1] Advances in genomic technologies, bioinformatics, and large-scale population studies have revealed that interindividual differences in genes encoding drug-metabolizing enzymes, transporters, and drug targets can profoundly affect pharmacokinetics, pharmacodynamics, and overall therapeutic outcomes.[2,3] This knowledge provides a foundation for precision medicine strategies that improve patient care, reduce healthcare costs, and enhance drug development efficiency.

The relevance of pharmacogenomics is underscored by the high prevalence of adverse drug reactions, which are estimated to account for a significant proportion of hospitalizations and healthcare expenditures globally.[4] For example, variations in the CYP450 enzyme family, particularly CYP2D6, CYP2C9, and CYP2C19, have been shown to alter the metabolism of a wide range of drugs, including antidepressants, anticoagulants, and antiplatelet agents.[5,6] Patients with specific polymorphisms may experience subtherapeutic effects or toxicities if standard dosing regimens are applied, highlighting the necessity of integrating genetic information into clinical decision-making.[7] Beyond metabolism, genetic variations in drug targets, such as receptor polymorphisms, and transport proteins, such as ABC transporters, further modulate drug response and resistance, demonstrating the multifactorial nature of pharmacogenomic influence.[8]

Recent advances in high-throughput genomic sequencing, genome-wide association studies (GWAS), and next-generation sequencing (NGS) technologies have accelerated the identification of clinically relevant genetic variants.[9] These discoveries have enabled the development of pharmacogenomic testing panels that are increasingly incorporated into clinical practice, guiding therapeutic decisions in oncology, cardiology, psychiatry, and infectious diseases.[10] In oncology, for instance, the use of tumor and germline genetic profiling informs drug selection, dosing, and monitoring for agents such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics, thereby improving treatment outcomes and reducing toxicity.[11] Similarly, in cardiology, genotyping for variants in VKORC1 and CYP2C9 informs individualized warfarin dosing, substantially decreasing the risk of bleeding and thromboembolic events.[12]

The integration of pharmacogenomics into personalized medicine is not limited to individual patient care; it also influences drug discovery and development. Incorporating genetic data early in the drug development process can identify patient subgroups more likely to respond to therapy, optimize clinical trial design, and potentially rescue compounds that failed in conventional trials due to population variability in drug response.[13] Furthermore, pharmacogenomic insights facilitate the repurposing of existing drugs for genetically defined patient populations, thereby enhancing precision therapeutics and addressing unmet clinical needs.[14]

Despite its promise, the clinical implementation of pharmacogenomics faces several challenges. Limitations include the complexity of polygenic influences on drug response, the need for standardized testing protocols, the integration of genetic data into electronic health records, and the education of healthcare providers regarding interpretation and application of results.[15] Ethical, legal, and social considerations, including patient consent, data privacy, and equitable access to testing, also pose significant hurdles.[16] Additionally, variability in healthcare systems and regulatory frameworks across countries impacts the adoption and reimbursement of pharmacogenomic-guided therapies.[17]

Looking forward, the convergence of pharmacogenomics with other emerging fields such as epigenomics, metabolomics, and artificial intelligence promises to enhance the predictive power of personalized medicine. Multi-omic approaches allow for a more comprehensive understanding of individual variability in drug response, while AI-driven algorithms can integrate genetic, clinical, and environmental data to generate actionable insights at the point of care.[18] These innovations are poised to transform the landscape of precision medicine, enabling truly individualized therapeutic strategies that optimize efficacy, safety, and patient outcomes.

In summary, pharmacogenomics represents a transformative approach to personalized medicine, providing a scientific basis for tailoring therapy to individual genetic profiles. Its current applications span multiple therapeutic areas, demonstrating tangible benefits in optimizing drug efficacy, minimizing adverse effects, and guiding drug development. At the same time, ongoing advancements in genomic technologies, computational tools, and multi-omic integration promise to expand the scope and impact of pharmacogenomics in the future. This review explores the current landscape of pharmacogenomics, examines clinical applications, and discusses future directions for advancing personalized medicine through genetics-driven therapy.

## METHODOLOGY

This review was conducted through a structured literature search across PubMed, Scopus, Web of Science, and Google Scholar using keywords such as “pharmacogenomics,” “personalized medicine,” “genetic polymorphism,” “drug response variability,” and “precision therapy,” focusing on articles published in English from 2010 to 2026. Studies were included if they addressed genetic determinants of drug response, clinical implementation of pharmacogenomic testing, therapeutic applications, or computational and multi-omic approaches. Conference abstracts, non-peer-reviewed content, and studies lacking sufficient methodological detail or direct relevance to human pharmacogenomics were excluded. Data were extracted on gene-drug

associations, type of genetic variation, therapeutic area, clinical relevance, testing methodology, and observed outcomes. Computational and bioinformatic strategies, including genome-wide association studies, next-generation sequencing, and AI-driven predictive models, were also noted. The extracted information was synthesized qualitatively to provide a comprehensive overview of current applications, clinical impact, challenges, and future directions in pharmacogenomics-guided personalized medicine.

## 1. Basic Concepts of Pharmacogenomics

### 1.1 Pharmacogenetics vs. Pharmacogenomics

Pharmacogenetics and pharmacogenomics are closely related but distinct concepts in precision medicine. Pharmacogenetics focuses on the study of how variations in a single gene influence an individual's response to a specific drug.[19] In contrast, pharmacogenomics examines the effects of multiple genes across the genome, assessing how genome-wide variations collectively impact drug efficacy, safety, and overall therapeutic outcomes.[20] While pharmacogenetics is often applied to targeted gene-drug interactions, pharmacogenomics enables broader insights into complex, multi-gene influences on drug response.

### 1.2 Genetic Variations Affecting Drug Response

Genetic variations are central to interindividual differences in drug response. Key types of variations include:

Single nucleotide polymorphisms (SNPs): Single base-pair changes in DNA that can alter drug metabolism or target interactions.[21]

Copy number variations (CNVs): Changes in the number of copies of a gene that can influence protein expression levels and drug processing.[22]

Insertions and deletions (indels): Addition or loss of DNA segments that may affect gene function or expression.[23]

These genetic variations can impact several pharmacological processes:

Drug metabolism: Variations in genes encoding metabolizing enzymes, such as CYP450 isoforms, can lead to differences in drug clearance and plasma levels.[24]

Drug transport: Genetic differences in transport proteins, like ABC transporters, can affect drug absorption, distribution, and elimination.[25]

Drug targets: Variations in receptors, enzymes, or other drug targets can modify therapeutic efficacy or susceptibility to adverse effects.[26]

Understanding these variations provides the foundation for tailoring drug therapy to individual genetic profiles, forming the basis of personalized medicine and optimizing treatment outcomes.

## 2. Key Pharmacogenes and Their Clinical Relevance

### 2.1 Drug-Metabolizing Enzymes

Drug-metabolizing enzymes play a central role in determining how individuals process medications. The cytochrome P450 (CYP450) enzyme family, including CYP2D6, CYP2C9, and CYP3A4, is particularly important. Genetic polymorphisms in these enzymes can result in distinct metabolizer phenotypes: poor, intermediate, extensive, or ultra-rapid metabolizers.[27] These variations directly affect drug clearance, plasma concentrations, therapeutic efficacy, and the risk of adverse drug reactions.[28] For example, CYP2D6 polymorphisms influence the metabolism of antidepressants, beta-blockers, and opioids, impacting both efficacy and safety.[29]

### 2.2 Drug Transporters

Drug transporters regulate the absorption, distribution, and excretion of many therapeutics. P-glycoprotein (ABCB1) is a well-studied efflux transporter that affects drug bioavailability and resistance, particularly in oncology and antiviral therapy.[30] Variants in ABCB1 and other transporters, such as organic anion transporters (OATs), can modify drug exposure, contributing to interindividual variability in response and toxicity.[25]

### 2.3 Drug Targets

Genetic variation in drug targets can alter drug sensitivity and therapeutic outcomes. For instance, VKORC1 polymorphisms influence warfarin sensitivity, guiding individualized dosing to minimize bleeding risk.[31] Similarly, TPMT variants affect thiopurine metabolism, with deficient alleles predisposing patients to severe myelosuppression.[32] These examples illustrate that variability in pharmacogenes, whether related to metabolism, transport, or targets, significantly shapes both efficacy and adverse effect profiles, underscoring the clinical relevance of genetic testing in personalized medicine.

## 3. Current Applications in Personalized Medicine

### 3.1 Oncology

Pharmacogenomics has become integral to targeted cancer therapy. Tumor genetic profiling allows clinicians to select therapies tailored to the molecular characteristics of the cancer, enhancing therapeutic efficacy while minimizing adverse effects.[33] For example, mutations in EGFR, BRAF, and ALK guide the use of tyrosine kinase inhibitors and other targeted agents, improving response rates and patient outcomes.[34] Additionally, germline variants can influence drug metabolism and toxicity, further supporting individualized treatment plans.[35]

### 3.2 Cardiology

In cardiology, pharmacogenomic testing informs anticoagulant and antiplatelet therapy. Warfarin dosing is

optimized based on CYP2C9 and VKORC1 genotypes, reducing the risk of bleeding and thromboembolic complications.[36] Similarly, CYP2C19 polymorphisms affect clopidogrel metabolism, influencing platelet inhibition and cardiovascular event outcomes.[37] Incorporating genotypic information into prescribing decisions enhances both safety and efficacy in cardiovascular care.

### 3.3 Psychiatry

Pharmacogenomics also plays a significant role in psychiatry, particularly in guiding antidepressant therapy. Variations in CYP2D6 and CYP2C19 affect the metabolism of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants.[38] By accounting for these genetic differences, clinicians can reduce trial-and-error prescribing, minimize adverse drug reactions, and improve treatment response, promoting more precise and effective mental health care.

### 3.4 Infectious Diseases

Genetic factors similarly influence responses to antiviral and antimicrobial therapies. Host genetic variations can affect drug metabolism, efficacy, and the risk of adverse reactions.[39] For instance, HLA-B*57:01 testing before abacavir therapy prevents hypersensitivity reactions in HIV treatment.[40] Clinical guidelines, such as those provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC), and curated resources like PharmGKB, support genotype-guided prescribing decisions across multiple therapeutic areas, enabling safer and more effective individualized treatments.[41]

Several well-characterized gene-drug interactions that illustrate how pharmacogenomic testing can guide therapy selection, optimize dosing, and minimize adverse effects are summarized in **Table 1.**

**Table 1: Key pharmacogenomic gene-drug associations, their mechanisms, therapeutic areas, and clinical implications for personalized medicine.**

| Gene / Variant | Drug | Therapeutic Area | Mechanism / Impact | Clinical Implication | Ref |
|---|---|---|---|---|---|
| CYP2C19 (*2, *3) | Clopidogrel | Cardiovascular | Reduced conversion to active metabolite → decreased platelet inhibition | Poor metabolizers may require alternative antiplatelet therapy | 42,43 |
| CYP2C9 (*2, *3) & VKORC1 | Warfarin | Cardiovascular | Altered metabolism and sensitivity → increased bleeding risk | Genotype-guided dosing reduces adverse events | 44,45 |
| TPMT (*2, *3A, *3C) | Azathioprine, 6-Mercaptopurine | Oncology / Immunology | Reduced enzyme activity → increased risk of myelosuppression | Pre-treatment testing guides dose adjustment | 46–48 |
| SLCO1B1 (*5, *15) | Simvastatin | Cardiovascular | Impaired hepatic uptake → increased plasma concentration | High-risk patients may need dose reduction to prevent myopathy | 49,50 |
| HLA-B*57:01 | Abacavir | Infectious diseases (HIV) | Immune-mediated hypersensitivity reaction | Screening prevents severe adverse reactions | 51,52 |
| HER2 amplification | Trastuzumab | Oncology (Breast, Gastric) | Overexpression drives tumor growth → targeted inhibition | Guides therapy selection for improved outcomes | 53,54 |
| CYP2D6 (*3, *4, *5, *6) | Tamoxifen, Codeine | Oncology / Pain management | Poor metabolizers → reduced active metabolite formation | Dose adjustment or alternative therapy recommended | 55,56 |
| UGT1A1 (*28) | Irinotecan | Oncology | Reduced glucuronidation → increased toxicity | Dose adjustment reduces risk of neutropenia and diarrhea | 57,58 |

## 4. Technologies Enabling Pharmacogenomics

### 4.1 Genomic Sequencing

Advances in genomic sequencing have transformed pharmacogenomics by enabling comprehensive analysis of genetic variation. Next-generation sequencing (NGS) allows high-throughput interrogation of DNA, facilitating the identification of clinically relevant variants.[59] Both whole-genome sequencing (WGS) and whole-exome sequencing (WES) provide detailed information on coding and non-coding regions, supporting the discovery of novel pharmacogenes and informing individualized therapy decisions.[60]

### 4.2 Molecular Techniques

Classical molecular methods remain essential for targeted pharmacogenomic testing. Polymerase chain

reaction (PCR)-based genotyping enables rapid detection of specific single nucleotide polymorphisms (SNPs) and other variants in clinically actionable genes.[61] Microarray technologies allow parallel analysis of multiple genetic markers, making them suitable for panel-based pharmacogenomic testing in clinical practice. These methods provide accurate, cost-effective, and scalable solutions for routine genotyping.[62]

### 4.3 Bioinformatics and Artificial Intelligence

The integration of genomic, transcriptomic, and proteomic data requires advanced computational tools. Bioinformatics platforms facilitate multi-omics data integration, variant annotation, and pathway analysis, enabling a systems-level understanding of drug response.[63] Artificial intelligence (AI) and machine learning algorithms further enhance predictive modeling, identifying complex gene-drug interactions and patient-specific response patterns.[64,65] These technologies improve the accuracy and clinical utility of pharmacogenomic models, supporting precision therapy across diverse populations.

Recent advancements in genomics and computational tools have significantly enhanced the predictive accuracy of pharmacogenomic models, accelerating the translation of genetic insights into clinical practice and enabling more personalized, safe, and effective therapeutic interventions.[33]

## 5. Benefits of Pharmacogenomics

Pharmacogenomics offers multiple advantages that enhance the safety, efficacy, and efficiency of medical treatment. By tailoring therapy to an individual's genetic profile, it enables improved drug efficacy, ensuring that patients receive medications most likely to produce the desired therapeutic effect.[66] It also contributes to a reduction in adverse drug reactions (ADRs) by identifying individuals at risk for toxicity due to genetic variations in drug-metabolizing enzymes, transporters, or targets.[67] Additionally, pharmacogenomic insights facilitate optimized drug dosing, minimizing under- or over-treatment and reducing complications associated with inappropriate dosing.[19] Over time, these benefits can lead to more cost-effective therapy, as avoiding ineffective treatments and adverse events decreases overall healthcare expenditures. By reducing reliance on "trial-and-error" prescribing, pharmacogenomics not only enhances individualized care but also improves overall patient outcomes, supporting safer, more efficient, and evidence-driven clinical decision-making.[68,69]

## 6. Challenges and Limitations

Despite the growing promise of pharmacogenomics, several challenges continue to limit its widespread clinical adoption.

### 6.1 Clinical Implementation Barriers

A key obstacle is the lack of awareness and training among healthcare professionals, which can impede the integration of pharmacogenomic testing into routine care.[15] Additionally, limited infrastructure, particularly in developing countries, restricts access to reliable genotyping facilities and the capacity to interpret complex genetic data effectively.[70]

### 6.2 Economic Constraints

The high cost of genetic testing remains a significant barrier, and limited reimbursement policies further discourage adoption, particularly in resource-limited healthcare systems.[71] These economic constraints can restrict patient access and prevent broader implementation despite proven clinical utility.

### 6.3 Ethical and Legal Issues

Pharmacogenomics raises important ethical and legal considerations, including concerns over genetic data privacy and the potential for genetic discrimination in employment or insurance.[72] Ensuring robust legal protections and informed consent frameworks is essential to maintain patient trust and promote responsible use of genetic information.

### 6.4 Scientific Challenges

Scientific hurdles include limited pharmacogenomic data across diverse populations, which can reduce the generalizability of findings and perpetuate health disparities.[73] Additionally, the complexity of gene-environment interactions complicates the prediction of drug response, requiring sophisticated multi-omic and computational approaches to fully capture interindividual variability.[74]

Overall, while pharmacogenomics offers substantial benefits for personalized medicine, overcoming these clinical, economic, ethical, and scientific challenges is critical to enable widespread implementation and ensure equitable access to genetics-guided therapy.

## 7. Future Directions

The future of pharmacogenomics is closely linked to technological advancements and broader clinical integration.

### 7.1 Integration with Artificial Intelligence

Artificial intelligence (AI) has the potential to transform pharmacogenomics by analyzing large-scale genomic datasets and predicting individual drug responses with unprecedented precision. Machine learning algorithms can identify complex gene-drug interactions, optimize dosing strategies, and provide actionable insights for clinicians at the point of care, thereby enhancing the predictive power of personalized therapy.

### 7.2 Multi-Omics Approaches

The integration of genomics, proteomics, metabolomics, and transcriptomics—collectively referred to as multi-

omics—offers a more comprehensive understanding of interindividual variability in drug response. By considering multiple layers of biological regulation, multi-omics approaches can uncover novel biomarkers, refine therapeutic targets, and support more precise and individualized treatment plans.[75]

### 7.3 Expansion in Clinical Practice

The clinical application of pharmacogenomics is expected to expand significantly. Its use will likely increase in rare diseases and complex conditions, where individualized therapy can substantially improve outcomes.[76] Efforts to implement pharmacogenomic testing more broadly, including in developing countries and underrepresented populations, will be crucial to ensure equitable access to precision medicine.

### 7.4 Pharmacogenomics-Guided Drug Development

Pharmacogenomics is also poised to influence drug discovery and development, enabling the design of safer and more effective therapeutics.[76] By identifying patient subgroups with favorable genetic profiles, clinical trials can be optimized, adverse events minimized, and novel indications for existing drugs explored.[77] This approach promises to accelerate the development of precision therapies and improve the overall success rate of drug development pipelines.

Overall, these advancements suggest a future in which pharmacogenomics is fully integrated into clinical practice and drug development, offering more precise, effective, and safe therapies tailored to individual patients.

## DISCUSSION

Pharmacogenomics, the study of how genetic variation affects drug response, has become a cornerstone of personalized medicine, offering the potential to optimize therapeutic efficacy while minimizing adverse effects. The integration of pharmacogenomic data into clinical practice allows for more precise drug selection, dosage adjustment, and risk prediction, ultimately moving healthcare from a “one-size-fits-all” model toward individualized therapy.[78] This review has examined the current applications, emerging technologies, and future directions of pharmacogenomics, highlighting both its clinical promise and the challenges that remain for broader implementation.

A key mechanism underlying pharmacogenomic variability is genetic polymorphism in drug-metabolizing enzymes, transporters, and receptors. Variants in genes such as CYP2C9, CYP2C19, TPMT, and VKORC1 significantly influence the metabolism and therapeutic outcomes of widely used medications, including anticoagulants, antiplatelets, immunosuppressants, and antidepressants.[79] For instance, variations in CYP2C19 affect the conversion of clopidogrel into its active metabolite, influencing efficacy and risk of cardiovascular events, while TPMT polymorphisms dictate thiopurine toxicity in leukemia treatment.[80,81] These examples illustrate how pharmacogenomic profiling can guide drug choice and dosing, reduce adverse drug reactions, and improve clinical outcomes. Beyond metabolism, pharmacogenomics also informs therapy through gene-drug interactions affecting drug targets or disease pathways, expanding its utility in oncology, psychiatry, and infectious diseases.[82]

Clinical implementation of pharmacogenomics relies on both targeted and panel-based testing approaches. Single-gene tests are often employed when strong gene-drug associations are established, while multigene panels provide broader insight into multiple pharmacogenes, enabling simultaneous assessment of multiple therapies.[83] Advances in next-generation sequencing (NGS) and high-throughput genotyping have dramatically increased the feasibility, speed, and affordability of comprehensive pharmacogenomic profiling.[33] Integration with electronic health records (EHRs) and clinical decision support systems (CDSS) further facilitates translation of genomic data into actionable prescribing recommendations, although interoperability and data standardization remain ongoing challenges.[84]

The review highlights several areas where pharmacogenomics has already demonstrated clinical utility. In oncology, precision prescribing guided by somatic and germline mutations has improved therapeutic outcomes and minimized toxicity, exemplified by targeted therapies such as trastuzumab in HER2-positive breast cancer and imatinib in BCR-ABL-positive leukemia.[85] In psychiatry, pharmacogenomic-guided antidepressant selection reduces trial-and-error prescribing and enhances treatment adherence.[86] Cardiovascular medicine benefits from genotype-informed anticoagulant dosing, minimizing hemorrhagic or thrombotic complications.[87] Collectively, these applications underscore pharmacogenomics’ capacity to enhance both efficacy and safety across diverse therapeutic domains.

Despite these advances, several barriers impede widespread adoption of pharmacogenomics in routine clinical practice. First, evidence gaps remain for many gene-drug pairs, particularly in ethnically diverse populations, raising concerns about generalizability.[88] Second, clinical guidelines and reimbursement policies vary widely, limiting access to testing.[89] Third, the interpretation of complex genomic data requires specialized expertise, and physicians may lack training or confidence in incorporating genetic information into prescribing decisions.[90] Ethical, legal, and social implications, including patient privacy, data security, and potential discrimination, further complicate implementation.[91] Addressing these challenges requires continued research, standardized testing protocols, and integration of pharmacogenomic education into medical curricula.

Future directions in pharmacogenomics are increasingly driven by systems medicine and integrative approaches. Multi-omics analyses combining genomics, transcriptomics, proteomics, and metabolomics offer a more holistic understanding of individual drug responses.[92] Artificial intelligence and machine learning algorithms can analyze complex datasets to predict adverse reactions or identify optimal drug regimens.[65,93] Moreover, large-scale population-based studies and biobank initiatives are enhancing our understanding of rare variants and their clinical relevance.[94] Personalized medicine is also expanding beyond pharmacogenomics to include environmental, lifestyle, and microbiome factors, providing a truly individualized approach to therapy.[78]

Therefore, pharmacogenomics has transitioned from a research focus to a clinically actionable tool, demonstrating substantial impact on drug selection, dosing, and patient outcomes. While challenges in evidence generation, clinical integration, and ethical considerations remain, technological advances, computational tools, and growing clinical awareness are accelerating its adoption. Pharmacogenomics represents a critical component of personalized medicine, offering the promise of safer, more effective, and patient-centered therapeutic strategies. Continued multidisciplinary collaboration, investment in infrastructure, and patient engagement will be essential to realize its full potential in routine clinical care.

## CONCLUSION

Pharmacogenomics has established itself as a cornerstone of personalized medicine by providing actionable insights into how genetic variability influences drug response. Evidence from oncology, cardiology, psychiatry, and other therapeutic areas demonstrates that pharmacogenomic-guided therapy can improve efficacy, reduce adverse effects, and optimize dosing strategies. Advances in sequencing technologies, multi-gene panels, and computational tools are enhancing the feasibility and accuracy of clinical implementation. However, challenges remain, including limited evidence for certain gene-drug pairs, disparities in access and reimbursement, clinician training gaps, and ethical considerations surrounding genetic data. Addressing these barriers through standardized protocols, education, and integrative multi-omics approaches will be critical for broader adoption. Overall, pharmacogenomics represents a transformative and evidence-driven approach to individualized therapy, with the potential to improve patient outcomes, inform clinical decision-making, and advance the future of precision medicine.

## ACKNOWLEDGEMENT

None.

## Conflict of Interest

Nil.

## REFERENCES

1. Alzahrani A, Alotaibi T, Al-Matroodi H, et al. The Role of Pharmacogenomics in Personalized Drug Therapy. *Saudi J Med Public Heal*., 2024; 1: 985-995. doi:10.64483/202412261
2. Lauschke VM, Zhou Y, Ingelman-Sundberg M. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. *Pharmacol Ther*., 2019; 197: 122-152. doi:https://doi.org/10.1016/j.pharmthera.2019.01.002
3. Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. *Genomics Proteomics Bioinformatics*, 2016; 14(5): 298-313. doi:10.1016/j.gpb.2016.03.008
4. Marques-garcia F, Martinez-bravo C. A review of pharmacogenomics in the individualization of pharmacological treatment : present and future, 2026; (January): 0-2. doi:10.21037/jlpm-25-9
5. Morais SL, Gonçalves TFC, Delerue-Matos C, et al. Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations. *Hum Gene*., 2022; 33: 201027. doi:https://doi.org/10.1016/j.humgen.2022.201027
6. Arici M, Özhan G. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. *Saudi Pharm J SPJ Off Publ Saudi Pharm Soc*., 2017; 25(3): 376-380. doi:10.1016/j.jsps.2016.09.003
7. Naderi N, Jolfayi AG, Azimi A, Maleki M, Kalayinia S. Pharmacogenomics in cardiac therapy: Personalizing treatment for heart health. *Biomed Pharmacother*, 2025; 190: 118392. doi:https://doi.org/10.1016/j.biopha.2025.118392
8. Moore JM, Bell EL, Hughes RO, Garfield AS. ABC transporters: human disease and pharmacotherapeutic potential. *Trends Mol Med*., 2023; 29(2): 152-172. doi:https://doi.org/10.1016/j.molmed.2022.11.001
9. Satam H, Joshi K, Mangrolia U, et al. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology (Basel)*, 2023; 12(7). doi:10.3390/biology12070997
10. Brlek P, Bulić L, Bračić M, et al. Implementing Whole Genome Sequencing (WGS) in Clinical Practice: Advantages, Challenges, and Future Perspectives. *Cells*, 2024; 13(6). doi:10.3390/cells13060504
11. Wang Y, Jiang C, Zhou H, Han R. Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer. *Exp Hematol Oncol*, 2025; 14(1): 114. doi:10.1186/s40164-025-00705-9
12. Bala A, Sundari T, Lukka H, Kumar VN. Single Nucleotide Polymorphisms in CYP2C9 and VKORC1 : Implications for Warfarin Dosing in South Indian Population with Venous

Thromboembolism, 2025; 16(10): 45-48. doi:10.25258/ijpqa.16.10.9
13. Rani R. Pharmacogenomics in Drug Development: From Discovery to Clinical Trials, 2025; 54: 1238-1262.
14. Srivastav AK, Mishra MK, Lillard JWJ, Singh R. Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine. *Pharmaceutics*, 2025; 17(5). doi:10.3390/pharmaceutics17050555
15. Mai CW, Sridhar SB, Karattuthodi MS, et al. Scoping review of enablers and challenges of implementing pharmacogenomics testing in the primary care settings. *BMJ Open*., 2024; 14(11): e087064. doi:10.1136/bmjopen-2024-087064
16. Tripura U, Nagrale NV, Singh OG, Dey A, Venkatesh J. Ethical, Social, and Legal Issues Related to Precision Medicine in India: Challenges and Solutions. *Ann Afr Med*., 2026; 25(1): 13-15. doi:10.4103/aam.aam_13_25
17. Omran S, Gan SH, Teoh SL. Pharmacogenomics in drug therapy: global regulatory guidelines for managing high-risk drug reactions. *Eur J Hum Genet*, 2026; 34(1): 27-36. doi:10.1038/s41431-025-01950-6
18. Zack M, Stupichev DN, Moore AJ, et al. Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine. *Mayo Clin proceedings Digit Heal*., 2025; 3(3): 100246. doi:10.1016/j.mcpdig.2025.100246
19. Oates JT, Lopez D. Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. *Int J Biomed Investig*, 2018; 1(2). doi:10.31531/2581-4745.1000111
20. Lauschke VM, Ingelman-Sundberg M. The evolving landscape of pharmacogenomics: Current achievements and future directions. *Pharmacol Rev*., 2026; 78(2): 100122. doi:https://doi.org/10.1016/j.pharmr.2026.100122
21. Lee NH. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. *Anticancer Agents Med Chem*., 2010; 10(8): 583-592. doi:10.2174/187152010794474019
22. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. *Trends Mol Med*., 2011; 17(5): 244-251. doi:10.1016/j.molmed.2011.01.007
23. Lutz S, Brion C, Kliebhan M, Albert FW. DNA variants affecting the expression of numerous genes in trans have diverse mechanisms of action and evolutionary histories. *PLoS Genet*., 2019; 15(11): e1008375. doi:10.1371/journal.pgen.1008375
24. Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, et al. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. *Biomedicines*, 2024; 12(7). doi:10.3390/biomedicines12071467
25. Kiełbowski K, Król M, Bakinowska E, Pawlik A. The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug-Drug Interactions. *Membranes (Basel)*, 2024; 14(11). doi:10.3390/membranes14110223
26. Veale CGL, Edkins AL. Genetic Variation in Drug Targets: Are We Ready for the Era of Precision Medicinal Chemistry? *ACS Med Chem Lett*., 2025; 16(5): 706-710. doi:10.1021/acsmedchemlett.5c00153
27. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther*., 2013; 138(1): 103-141. doi:https://doi.org/10.1016/j.pharmthera.2012.12.007
28. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. *Curr Drug Metab*., 2011; 12(5): 487-497. doi:10.2174/138920011795495321
29. Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. *Expert Opin Drug Metab Toxicol*, 2022; 18(11): 769-785. doi:10.1080/17425255.2022.2160317
30. Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. P-glycoprotein and cancer: what do we currently know? *Heliyon*, 2022; 8(10): e11171. doi:https://doi.org/10.1016/j.heliyon.2022.e11171
31. Yan X, Yang F, Zhou H, et al. Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population. *Med Sci Monit Int Med J Exp Clin Res*., 2015; 21: 3577-3584. doi:10.12659/msm.894414
32. Nguyen CM, Mendes MAS, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. *PLoS Curr*., 2011; 3: RRN1236. doi:10.1371/currents.RRN1236
33. Jamalinia M, Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. *Ann Transl Med*., 2025; 13(2): 18. doi:10.21037/atm-25-34
34. Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. *J Thorac Oncol*, 2021; 16(5): 764-773. doi:https://doi.org/10.1016/j.jtho.2020.12.002
35. Kaehler M, Cascorbi I. Germline variants in cancer therapy. *Cancer drug Resist (Alhambra, Calif)*., 2019; 2(1): 18-30. doi:10.20517/cdr.2019.05
36. Fung E, Patsopoulos NA, Belknap SM, et al. Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. *Semin Thromb Hemost*, 2012; 38(8): 893-904. doi:10.1055/s-0032-1328891
37. Sun Y, Lu Q, Tao X, Cheng B, Yang G. Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in

Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis. *Front Genet*., 2020; 11: 576046. doi:10.3389/fgene.2020.576046
38. Austin-Zimmerman I, Wronska M, Wang B, et al. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics. *Genes (Basel)*. 2021; 12(11). doi:10.3390/genes12111758
39. Principi N, Petropulacos K, Esposito S. Genetic Variations and Antibiotic-Related Adverse Events. *Pharmaceuticals (Basel)*. 2024; 17(3). doi:10.3390/ph17030331
40. Gautam A, Chakravarty J, Chourasia A, Sharma S, Sarkar T, Das P. Prevalence of HLA-B*57:01 allele in HIV-positive and HIV-negative population of eastern India: An epidemiological study. *Clin Epidemiol Glob Heal*., 2022; 18: 101181. doi:https://doi.org/10.1016/j.cegh.2022.101181
41. Relling M V, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. *Clin Pharmacol Ther*., 2020; 107(1): 171-175. doi:10.1002/cpt.1651
42. Dean L. Clopidogrel Therapy and CYP2C19 Genotype, 2018; (MD): 1-13.
43. Singh M, Shah T, Adigopula S, et al. CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: Is clinical testing helpful? *Indian Heart J*., 2012; 64(4): 341-352. doi:https://doi.org/10.1016/j.ihj.2012.06.003
44. Alrashid M, Al-Serri A, Alshemmari S, Mundamattom P, Al-Bustan S. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals. *Mol Diagn Ther*., 2016; 20. doi:10.1007/s40291-016-0190-7
45. Jokhab S, AlRasheed MM, Bakheet D, AlMomen A, AlAboud N, Kamali F. The impact of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin dose requirement in Saudi patients. *Front Pharmacol*, 2025; 16-2025. doi:10.3389/fphar.2025.1547142
46. Hessels AC, Rutgers A, Sanders JSF, Stegeman CA. Thiopurine methyltransferase genotype and activity cannot predict outcomes of azathioprine maintenance therapy for antineutrophil cytoplasmic antibody associated vasculitis: A retrospective cohort study. *PLoS One*, 2018; 13(4): e0195524. doi:10.1371/journal.pone.0195524
47. Appell M, Berg J, Duley J, et al. Nomenclature for alleles of the thiopurine methyltransferase (TPMT) gene. *Pharmacogenet Genomics*, 2013; 23: 242-248. doi:10.1097/FPC.0b013e32835f1cc0
48. Dean L. Azathioprine Therapy and TPMT Genotype Drug Class : Thiopurines Drug : Azathioprine, 2016; (Md): 1-7.
49. de Keyser C, Peters B, Becker M, et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. *Pharmacogenet Genomics*, 2013; 24. doi:10.1097/FPC.0000000000000018 111111111.pdf.
50. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 Screening for Hypersensitivity to Abacavir. *N Engl J Med*., 2008; 358: 568-579. doi:10.1056/NEJMoa0706135
51. Mounzer K, Hsu R, Fusco JS, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study. *AIDS Res Ther*., 2019; 16(1): 1. doi:10.1186/s12981-019-0217-3
52. Xu L, Xie Y, Gou Q, et al. HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future. *Front Pharmacol*, 2024; 15. doi:10.3389/fphar.2024.1446414
53. Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. *Nat Rev Drug Discov*, 2023; 22(2): 101-126. doi:10.1038/s41573-022-00579-0
54. Dean L, Kane M. Codeine Therapy and CYP2D6 Genotype, 2026; (MD): 1-17.
55. Maggadani BP, Junusmin KI, Aldila F, et al. CYP2D6 Genotyping for Optimization of Tamoxifen Therapy in Indonesian Women with ER + Breast Cancer. Published online 2025.
56. Geng S, Shen Y, Zhang C, et al. Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients. *Front Pharmacol*, 2025; 16. doi:10.3389/fphar.2025.1563566
57. Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR. Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. *World J Gastroenterol*, 2013; 19(24): 3899-3903. doi:10.3748/wjg.v19.i24.3899
58. Qin D. Next-generation sequencing and its clinical application. *Cancer Biol Med*., 2019; 16(1): 4-10. doi:10.20892/j.issn.2095-3941.2018.0055
59. Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. *Proc Natl Acad Sci U S A*., 2015; 112(17): 5473-5478. doi:10.1073/pnas.1418631112
60. Lawrie RD, Massey SE. Agrigenomic Diversity Unleashed : Current Single Nucleotide Polymorphism Genotyping Methods for the Agricultural Sciences. Published online, 2023; 565-585.
61. van der Lee M, Kriek M, Guchelaar HJ, Swen JJ. Technologies for Pharmacogenomics: A Review. *Genes (Basel)*, 2020; 11(12). doi:10.3390/genes11121456
62. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics Data Integration, Interpretation, and Its Application. *Bioinform Biol Insights*, 2020; 14: 1177932219899051.

doi:10.1177/1177932219899051
63. Lu Y, Chen J, Fan N, et al. Machine learning models for drug-drug interaction prediction from computational discovery to clinical application. Published online 2026.
64. Serrano DR, Luciano FC, Anaya BJ, et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. *Pharmaceutics*, 2024; 16(10). doi:10.3390/pharmaceutics16101328
65. Eskandar K. Pharmacogenomics : tailoring drug therapy to individual patients. *J la Fac médecine d Oran*, 2024; 8: 991-998. doi:10.51782/jfmo.v8i1.223
66. Ray SD, Mirza M, Ramlakhan K, Elayan I, Hussain A, D'Souza MS. Chapter 37 - Association of pharmacogenomics with ADRs, ADEs and toxicity of different classes of drugs. In: Ray SD, ed. Vol 47. Side Effects of Drugs Annual. Elsevier, 2025; 457-471. doi:https://doi.org/10.1016/bs.seda.2025.09.013
67. Ibrahim F. Pharmacogenomics in personalized medicine: Revolutionizing drug development and patient outcomes. *Int J Biol Pharm Sci Arch*., 2025; 9: 115-129. doi:10.53771/ijbpsa.2025.9.2.0043
68. McDermott JH, Sharma V, Keen J, Newman WG. Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes. *Ann Hum Genet*., 2025; 89(5): 398-405. doi:10.1111/ahg.12601
69. Carvajal-Yepes M, Petroli C, Correa M, et al. Strengthening national genebanks through genomics and regional collaboration: Lessons from Latin America and the Caribbean. *Glob Food Sec*., 2026; 48: 100899. doi:https://doi.org/10.1016/j.gfs.2025.100899
70. Goldin MR, Ruderfer DM, Bick A, Roden DM, Schuler BA, Robinson JR. Benefits and barriers to broad implementation of genomic sequencing in the NICU. *Am J Hum Genet*., 2025; 112(6): 1270-1285. doi:https://doi.org/10.1016/j.ajhg.2025.04.007
71. Shields AE. Ethical concerns related to developing pharmacogenomic treatment strategies for addiction. *Addict Sci Clin Pract*, 2011; 6(1): 32-43.
72. Ayati N, Afzali M, Hasanzad M, Kebriaeezadeh A, Rajabzadeh A, Nikfar S. Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country. *Iran J Pharm Res IJPR*., 2021; 20(4): 92-106. doi:10.22037/ijpr.2021.114899.15091
73. Alemu R, Sharew NT, Arsano YY, et al. Multi-omics approaches for understanding gene-environment interactions in noncommunicable diseases: techniques, translation, and equity issues. *Hum Genomics*, 2025; 19(1): 8. doi:10.1186/s40246-025-00718-9
74. Jiang Z, Zhang H, Gao Y, Sun Y. Multi-omics strategies for biomarker discovery and application in personalized oncology. *Mol Biomed*, 2025; 6(1): 115. doi:10.1186/s43556-025-00340-0
75. Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. *Pharmaceuticals (Basel)*, 2024; 17(7). doi:10.3390/ph17070940
76. Marques L, Costa B, Pereira M, et al. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. *Pharmaceutics*, 2024; 16(3). doi:10.3390/pharmaceutics16030332
77. Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. *Biomedicines*, 2024; 12(12). doi:10.3390/biomedicines12122750
78. Rackow AR, Snyder I, Stevenson JM, Knezevic CE, Marzinke MA. Evaluation of the availability of clinical pharmacogenomics within the USA and utilization within an academic healthcare system. Published online, 2025; 0-2. doi:10.21037/jlpm-25-25
79. Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. *J Pers Med*., 2018; 8(1). doi:10.3390/jpm8010008
80. Abaji R, Krajinovic M. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response. *Pharmgenomics Pers Med*., 2017; 10: 143-156. doi:10.2147/PGPM.S108123
81. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: Driving Personalized Medicine. *Pharmacol Rev*., 2023; 75(4): 789-814. doi:10.1124/pharmrev.122.000810
82. Rouby N El, Allen JD, Koep T, et al. Gene Pharmacogenomic Testing in a Community- - Based Setting Is Feasible and Reduces Total Healthcare Costs. Published online, 2025; 1-8. doi:10.1111/cts.70418
83. Solomon J, Dauber-Decker K, Richardson S, et al. Integrating Clinical Decision Support Into Electronic Health Record Systems Using a Novel Platform (EvidencePoint): Developmental Study. *JMIR Form Res*., 2023; 7: e44065. doi:10.2196/44065
84. Brlek P, Škaro V, Hrvatin N, et al. Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies. *Cancers (Basel)*. 2025; 17(21). doi:10.3390/cancers17213500
85. Shields M, McAusland L, Heintz M, et al. Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial. *J Pers Med*., 2026; 16(2). doi:10.3390/jpm16020125
86. Mauriello A, Ascrizzi A, Molinari R, et al. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk. *Genes (Basel)*. 2023; 14(11). doi:10.3390/genes14112057

87. Magavern EF, Gurdasani D, Ng FL, Lee SSJ. Health equality, race and pharmacogenomics. *Br J Clin Pharmacol*, 2022; 88(1): 27-33. doi:10.1111/bcp.14983
88. Orangi S, Orangi T, Kabubei KM, Honda A. Understanding factors influencing the use of clinical guidelines in low-income and middle-income settings: a scoping review. *BMJ Open*, 2023; 13(6): e070399. doi:10.1136/bmjopen-2022-070399
89. Schaibley VM, Ramos IN, Woosley RL, Curry S, Hays S, Ramos KS. Limited Genomics Training Among Physicians Remains a Barrier to Genomics-Based Implementation of Precision Medicine. *Front Med*., 2022; 9: 757212. doi:10.3389/fmed.2022.757212
90. Brothers KB, Rothstein MA. Ethical, legal and social implications of incorporating personalized medicine into healthcare. *Per Med*., 2015; 12(1): 43-51. doi:10.2217/pme.14.65
91. Chen C, Wang J, Pan D, et al. Applications of multi-omics analysis in human diseases. *MedComm*. 2023; 4(4): e315. doi:10.1002/mco2.315
92. Chalabianloo N, Sedig K, Rostamzadeh N, Muanda FT, Izzedin L. Machine learning methods for predicting adverse drug events : A systematic review, 2026; (October 2025): 422-444. doi:10.1002/bcp.70377
93. Forrest IS, Huang KL, Eggington JM, Chung WK, Jordan DM, Do R. Using large-scale population-based data to improve disease risk assessment of clinical variants. *Nat Genet*, 2025; 57(7): 1588-1597. doi:10.1038/s41588-025-02212-3